In a move that should come as no surprise to many, the US FDA has requested Oncopeptides AB withdraw the NDA for Pepaxto (melphalan flufenamide), but that development is not necessarily the end of the saga for the product.
The FDA request, announced by Oncopeptides on 7 December, comes more than two months after the Oncologic Drugs Advisory Committee...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?